These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35253097)

  • 41. SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: A case report.
    Hasan DA; Maulud SQ; Jalal PJ; Priyanka ; Choudhary OP
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055947. PubMed ID: 35417318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
    Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
    Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
    Zhou Z; Zhu Y; Chu M
    Front Immunol; 2022; 13():898192. PubMed ID: 35669787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.
    Chen Z; Zhang Y; Wang M; Islam MS; Liao P; Hu Y; Chen X
    Int J Biol Sci; 2022; 18(12):4629-4641. PubMed ID: 35874952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence.
    Tatsi EB; Filippatos F; Michos A
    Epidemiol Infect; 2021 Nov; 149():e237. PubMed ID: 34732275
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
    Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
    Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
    Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
    J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One and a half years into the COVID-19 pandemic - exit strategies and efficacy of SARS-CoV-2 vaccines for holistic management and achieving global control.
    Petersen E; Gökengin D; Al Balushi A; Zumla A
    Turk J Med Sci; 2021 Dec; 51(SI-1):3157-3161. PubMed ID: 34284531
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Strategies and safety considerations of booster vaccination in COVID-19.
    Meng H; Mao J; Ye Q
    Bosn J Basic Med Sci; 2022 Jun; 22(3):366-373. PubMed ID: 35366790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pediatric humoral immune responses and infection risk after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and two-dose vaccination during SARS-CoV-2 omicron BA.5 and BN.1 variants predominance in South Korea.
    Choi HW; Achangwa C; Park J; Lee SM; Lee NY; Jeon CH; Choi JH; Do HK; Nam JH; Lee JW; Kim B; Ryu S; Kee SJ
    Front Immunol; 2023; 14():1306604. PubMed ID: 38193075
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2 variants - Evolution, spike protein, and vaccines.
    Chen KK; Tsung-Ning Huang D; Huang LM
    Biomed J; 2022 Aug; 45(4):573-579. PubMed ID: 35526825
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.
    Chakraborty C; Sharma AR; Bhattacharya M; Lee SS
    Front Immunol; 2022; 13():801522. PubMed ID: 35222380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan.
    Liu X; Mostafavi H; Ng WH; Freitas JR; King NJC; Zaid A; Taylor A; Mahalingam S
    mBio; 2022 Jun; 13(3):e0068322. PubMed ID: 35420469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.
    Cao M; Su X; Jiang S
    Stem Cell Reports; 2021 Mar; 16(3):398-411. PubMed ID: 33691145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses.
    Torresi J; Edeling MA; Nolan T; Godfrey DI
    Front Immunol; 2022; 13():914167. PubMed ID: 35911696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The COVID-19 pandemic: viral variants and vaccine efficacy.
    Ciotti M; Ciccozzi M; Pieri M; Bernardini S
    Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.